血衍生FVII度的使用在手术患者与因子VII缺乏症:一个案例系列
Paolo Conca1, Ernesto Cimino1, Anna Guida2
1Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
Seminars in thrombosis and hemostasis
|January 9, 2026
概括
血衍生非激活因子VII (pd-FVII) 度在患有因子VII缺乏症的患者中有效管理术前静血. 这种方法可以在手术过程中和手术后预防严重出血或血栓事件.
科学领域:
- 血液学 血液学 血液学
- 凝血障碍 凝血障碍 凝血障碍
背景情况:
- 遗传性第七因子 (FVII) 缺乏症是一种常见的罕见出血障碍.
- 获得的FVII缺陷可以单独发生或与其他因素缺陷一起发生.
- FVII水平不是出血风险的可靠预测指标,需要个性化手术管理.
研究的目的:
- 评估患有先天性或获得的FVII缺陷的患者的术后管理.
- 评估血衍生非活化FVII (pd-FVII) 缩剂在外科手术期间血液静止的疗效和安全性.
主要方法:
- 在2022年4月至2025年5月期间治疗的12名FVII缺乏症患者 (13例手术) (2例获得性,10例先天性) 的回顾性分析.
- 使用pd-FVII缩剂进行外科手术期间的预防,剂量为20-40 IU/kg/剂量.
- 在手术期间和之后监测出血和血栓事件.
主要成果:
- 在手术期间或手术后,在任何患者身上都没有观察到严重的出血或血栓事件.
- 一名患者经历了术后出血,没有报告其他重大并发症.
- 总的pd-FVII消耗量从20到320 IU/kg不等.
结论:
- 术后使用pd-FVII度是一种安全有效的策略,用于管理接受手术的因子VII缺乏症患者.
- 对出血史和手术类型的个性化评估对于最佳的术后护理至关重要.
- pd-FVII缩剂可提供可靠的血液静止,最大限度地降低了这种患者群体中与手术相关的风险.
相关概念视频
Venous Thrombosis III: Interprofessional Care
276
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
276
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
308
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
308
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


